Stay updated on Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page displays a new revision label: v3.3.2 replacing the previous v3.2.0.SummaryDifference0.1%

- Check28 days agoChange DetectedThe government funding status notice banner has been removed from the page, removing administrative operating information unrelated to trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedAdministrative metadata on the study record was updated between the screenshots. No modifications to the trial's objectives, eligibility criteria, dosing, endpoints, or enrollment were observed.SummaryDifference0.4%

- Check71 days agoChange DetectedAdded a government funding lapse notice and updated operating-status guidance, plus version bump to v3.2.0; removed the previous v3.1.0 tag.SummaryDifference2%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedUpdated to revision v3.0.2 (replacing v3.0.1) and removed the Back to Top element. This is a minor maintenance update with no changes to core content, pricing, stock, or time-sensitive information.SummaryDifference0.1%

Stay in the know with updates to Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.